Book a free demo with us
Book Now

Orasis Pharmaceuticals

WE INVITE CONSTRUCTIVE DISRUPTION. Orasis is an emerging ophthalmic pharmaceutical company with an FDA approved prescription eye drop, QLOSI™ (pilocarpine HCl ophthalmic solution) 0.4%, for presbyopia as an alternative to reading glasses. Presbyopia is the gradual loss of your eye’s ability to focus on near objects, which begins to affect most people sometime after the age of 40 and affects more than 1.8 billion people worldwide.

Total Fundraised$5B

PE Round
Late Stage
Debt Financing
Pre-IPO
Series C
Series B
Series A
Others
Calendar Image2015
Established
HeadquarterGradient ImagePonte Vedra Beach, Florida, United States
Headquarter
OperationalGradient Image
USA
ISR
Operational Market
SectorGradient Image
Healthcare
Pharmaceuticals
Pharmaceutical
Medical
Health Care
Healthtech
Primary Sector
EmployeeGradient Image2 - 10
Employees
PinGradient ImageSeries D
Current Stage
GlobeGradient Imagehttps://www.orasis-pharma.com/
Website

Funding Types by Funds Raised (in USD)

Content Locked

Login or Register a FREE account to continue browsing our content

Cumulative Funding Raised Over Time

Content Locked

Login or Register a FREE account to continue browsing our content

Orasis Pharmaceuticals's Investors by Funding Rounds

Funding Round

Announced Date

Disclosed Investors

Round Amount (USD)

Content Locked

Login or Register a FREE account to continue browsing our content

Orasis Pharmaceuticals's Key
Team Members

Elad Kedar
Paul Smith
Ron Neumann
Julie Speed